Conditions: Metastatic Esophageal; Gastric Cancer; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic HPV Related Solid Tumors; Metastatic Ovarian Carcinoma; Metastatic Soft Tissue Sarcoma; Metastatic Uveal Melanoma
Interventions: Drug: LVGN3616 + LVGN6051 + Nab-Paclitaxel; Drug: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; Drug: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel; Drug: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; Lyvgen Biopharma Holdings Limited
**RECRUITING NOW**
Interventions: Drug: LVGN3616 + LVGN6051 + Nab-Paclitaxel; Drug: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; Drug: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel; Drug: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; Lyvgen Biopharma Holdings Limited
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
